Author, year | Bone density | Bone gain | Bone resorption | MBL | Survival rate | Other findings | Complications |
---|---|---|---|---|---|---|---|
Chandra et al. 2019 [10] | a) BR group: 596.2 ± 115.2 HU b) SB group: 659.6 ± 133.8 HU *(p < 0.001) | a) BR group: 3.09 mm (buccal) and 3.31 mm (lingual) b) SB group: 1.90 mm (buccal) and 1.99 mm (lingual) *(p < 0.001) | – | – | a) BR group: 88,23% b) SB group: 100% | Implant Stability Quotient (ISQ) a) BR group: 61.60 ± 8.9 b) SB group: 45.02± 6.33 *(p < 0.034) Histological analysis a) BR group: 50.39% ± 11.96% b) SB group: 38.91% ± 12.22% *(p < 0.001) | a) BR group: -2 IOI and BR failure -1 dehiscence -3 swelling b) SB group: -1 dehiscence -3 swelling |
Flanagan et al. 2016 [17] | – | – | – | – | 100% | – | No complications |
Fukuda et al. 2005 [18] | – | – | – | – | 92.3% | Radiological stability between baseline and 1.3 years (periapical Rx) | 1 IOI and BR failure |
Giesenhagen et al. 2018 [19] | – | – | – | – | 100% | Radiological stability between baseline and 6 m (panoramic Rx) | No complications |
Giesenhagen et al. 2019 [20] | – | – | – | – | 100% | Clinical and radiological stability between baseline and 2 year (panoramic Rx) | – |
Giraddi et al. 2017 [21] | – | -Mesial bone gain: 3.70 ± 1.10 mm -Distal bone gain: 3.69 ± 1.10 mm | -Mesial bone resorption: 0.73 ± 0.38 mm -Distal bone resorption: 0.78 ± 0.23 mm | – | 93.33% | – | 1 IOI and BR failure |
Miller J. 2019 [22] | – | – | – | – | 100% | Radiological stability between baseline and 6 m (periapical Rx) ISQ 68 at 6 m | No complications |
Nord et al. 2019 [23] | – | – | – | 0.43 mm | 97.5% | – | 2 IOI failure |
Omara et al. 2016 [24] | -Mesial aspect: 420.43 HU -Distal aspect: 325.28 HU | 13.07 ± 1.37 mm | 0.26 ±0.86 mm | – | 100% | – | 2 transient numbness of lower lip |
Peñarrocha et al. 2005 [25] | – | – | – | – | 100% | Radiological stability between baseline and 2 years (panoramic Rx) | No complications |
Rizzo et al. 2017 [26] | – | – | – | z | 100% | Radiological stability between baseline and 6 years (periapical Rx) | No complications |
Sindel et al. 2018 [27] | - | – | – | 1.77 mm | 90% | – | 1 IOI and BR failure |
Stevenes et al. 2010 [28] | – | – | – | – | 100% | – | No complications |
Tekin et al. 2011 [29] | – | – | – | – | 100% | Radiological stability between baseline and 6 years (periapical Rx) | No complications |
Wychowansky et al. 2020 [11] | – | a) BR group: 4.3 ± 1.3 mm b) XG group: 4.4 ± 1.5 mm | – | – | a) BR group: 86,66% b) XG group: 96,66% | Implant stability at baseline (periotest) a) BR group: − 3.2 ± 1.3 b) XG group: − 1.2 ± 1.6 *(p<0,005) Implant stability at 24 m (periotest) a) BR group: − 3.7 ± 1.1 b) XG group: − 3.6 ± 1.2 *(p < 0.005) | a) BR group: -4 IOI failure b) XG group: -1 IOI failure |
Yuce et al. 2019 [12] | – | – | – | – | 100% | – | 1 BR failure (defect repaired and IOI osseointegrated) |